Expertise in

conditions

Jean-yves Y. Blay

Faculté De Médecine Lyon Est,

Lyon, FR

Expertise in

conditions

Faculté De Médecine Lyon Est,

Lyon, FR

Overview

Jean-yves Blay practices in Lyon, France. Blay is highly rated in 37 conditions, according to our data. Their top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Synovial Sarcoma, Pancreaticoduodenectomy, and Tissue Biopsy.

Their clinical research consists of co-authoring 599 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Faculté De Médecine Lyon Est, Lyon, France

Other Locations

CRCL
Lyon, France

CLB
Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Enrollment Status: Terminated

Publish Date: April 14, 2026

Intervention Type: Drug

Study Phase: Phase 1

A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas

Enrollment Status: Active_not_recruiting

Publish Date: April 13, 2026

Intervention Type: Drug, Other

Study Drug: Cabozantinib S-malate

Study Phase: Phase 2

Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy

Enrollment Status: Completed

Publish Date: March 18, 2026

Intervention Type: Drug

Study Drug: Regorafenib

Study Phase: Phase 2

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Enrollment Status: Active_not_recruiting

Publish Date: February 25, 2026

Intervention Type: Drug

Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide

Study Phase: Phase 2

A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Combination product

Study Drug: Atezolizumab

Study Phase: Phase 2

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

Enrollment Status: Active_not_recruiting

Publish Date: February 10, 2026

Intervention Type: Drug

Study Drugs: Pazopanib, HDM201

Study Phase: Phase 1/Phase 2

Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (CP) in Patients With Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II Study From the French Sarcoma Group.

Enrollment Status: Completed

Publish Date: January 14, 2026

Intervention Type: Drug

Study Drugs: Trabectedin, Cyclophosphamide

Study Phase: Phase 1/Phase 2

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial

Enrollment Status: Completed

Publish Date: December 10, 2025

Intervention Type: Drug

Study Drugs: MK3475, Pembrolizumab, Endoxan, Cyclophosphamide, G100, Metronomic

Study Phase: Phase 2

Study of Complications Related to Treatments in Adults Aged 18 to 65 Years Old Responding to a First Treatment in Oncology or Onco-hematology and Participating in the PASCA (PArcours de Santé au Cours du CAncer) Post-treatment Program.

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Other

Study Phase: Not Applicable

Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study

Enrollment Status: Completed

Publish Date: August 24, 2025

Intervention Type: Drug

Study Phase: Phase 2

View 9 Less Clinical Trials

597 Total Publications

Artificial intelligence in medicine: a scoping review of the risk of deskilling and loss of expertise among physicians.

Journal: ESMO real world data and digital oncology

Published: March 27, 2026

View All 597 Publications

Frequently Asked Questions about Jean-yves Y. Blay

Is Jean-yves Y. Blay a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-yves Y. Blay is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-yves Y. Blay participate in research or clinical trials?

Yes. Jean-yves Y. Blay has published 597 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Jean-yves Y. Blay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Blay's expertise for a condition

ConditionClose